PRTK - Increased Volume From Bounce. Could Keep Trending Up

٣٠ أغسطس ٢٠١٩

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

P/E Current
-0.95

P/E Ratio (with extraordinary items)
-0.89

Average Recommendation: BUY

Average Target Price: 21.33

SHORT INTEREST
10.98M 08/15/19